Iohexol

Details

Stereochemistry	MIXED
Molecular Formula	C19H26I3N3O9
Molecular Weight	821.1379
Optical Activity	UNSPECIFIED
Defined Stereocenters	0 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(=O)N(CC(O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I

InChI

InChIKey=NTHXOOBQLCIOLC-UHFFFAOYSA-N

InChI=1S/C19H26I3N3O9/c1-8(29)25(4-11(32)7-28)17-15(21)12(18(33)23-2-9(30)5-26)14(20)13(16(17)22)19(34)24-3-10(31)6-27/h9-11,26-28,30-32H,2-7H2,1H3,(H,23,33)(H,24,34)

HIDE SMILES / InChI

Molecular Formula	C19H26I3N3O9
Molecular Weight	821.1379
Charge	0
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	0 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018956s095,020608s031lbl.pdf
Curator's Comment: description was created based on several sources, including: http://www.drugbank.ca/drugs/DB01362 http://www.rxlist.com/omnipaque-drug.htm

Iohexol is a nonionic, water-soluble radiographic contrast medium. Organic iodine compounds block x-rays as they pass through the body, thereby allowing body structures containing iodine to be delineated in contrast to those structures that do not contain iodine. It is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Drugs which lower seizure threshold, especially phenothiazine derivatives including those used for their antihistaminic or antinauseant properties, are not recommended for use with Iohexol. Others include monoamine oxidase (MAO) inhibitors, tricyclic antidepressants, CNS stimulants, psychoactive drugs described as analeptics, major tranquilizers, or antipsychotic drugs. The most frequently reported adverse reactions are headache, mild to moderate pain including backache, neckache and stiffness, nausea, and vomiting.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
vessels and anatomical structures 3 Target ID: vessels and anatomical structures Sources: http://cursoenarm.net/UPTODATE/contents/mobipreview.htm?39/45/40669?source=see_link#F7983651	Activator 1447

Conditions

Condition	Modality	Highest Phase	Product
Spinal cord disease 2 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018956s095,020608s031lbl.pdf	Diagnostic	Approved 8583	OMNIPAQUE 300 Approved Use —Intrathecal OMNIPAQUE 300 is indicated for intrathecal administration in adults including myelography (lumbar, thoracic, cervical, total columnar) and in contrast enhancement for computerized tomography (myelography, cisternography, ventriculography)., INDICATIONS AND USAGE, GENERAL—Intravascular OMNIPAQUE 350 is indicated in adults for angiocardiography (ventriculography, selective coronary arteriography), aortography including studies of the aortic root, aortic arch, ascending aorta, abdominal aorta and its branches, contrast enhancement for computed tomographic head and body imaging, intravenous digital subtraction angiography of the head, neck, abdominal, renal and peripheral vessels, peripheral arteriography, and excretory urography. OMNIPAQUE 350 is indicated in children for angiocardiography (ventriculography, pulmonary arteriography, and venography; studies of the collateral arteries and aortography, including the aortic root, aortic arch, ascending and descending aorta). OMNIPAQUE 300 is indicated in adults for aortography including studies of the aortic arch, abdominal aorta and its branches, contrast enhancement for computed tomographic head and body imaging, cerebral arteriography, peripheral venography (phlebography), and excretory urography. OMNIPAQUE 300 is indicated in children for angiocardiography (ventriculography), excretory urography, and contrast enhancement for computed tomographic head imaging., INDIVIDUAL INDICATIONS AND USAGE, INDICATIONS AND USAGE, GENERAL—Oral/Body Cavity Use OMNIPAQUE 300 and OMNIPAQUE 350 have osmolalities from approximately 1.6 to 3.0 times that of plasma (285 mOsm/kg water) and are hypertonic under conditions of use. Adults OMNIPAQUE 350 is indicated in adults for arthrography and oral pass-thru examination of the gastrointestinal tract. OMNIPAQUE 300 is indicated in adults for arthrography and hysterosalpingography. OMNIPAQUE diluted to concentrations from 6 mgI/mL to 9 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously is indicated in adults for contrast enhanced computed tomography of the abdomen. Children OMNIPAQUE 300 is indicated in children for examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 50 mgI/mL to 100 mgI/mL is indicated in children for voiding cystourethrography. OMNIPAQUE diluted to concentrations from 9 mgI/mL to 21 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in children for use in contrast enhanced computed tomography of the abdomen., INDIVIDUAL INDICATIONS AND USAGE Oral Use Adults OMNIPAQUE 350 at a concentration of 350 mgI/mL is indicated in adults for use in oral pass-thru examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 6 mgI/mL to 9 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in adults for use in contrast enhanced computed tomography of the abdomen. Dilute oral plus intravenous OMNIPAQUE may be useful when unenhanced imaging does not provide sufficient delineation between normal loops of the bowel and adjacent organs or areas of suspected pathology. Children OMNIPAQUE 300 at a concentration of 300 mgI/mL administered orally or rectally is indicated in children for use in examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 9 mgI/mL to 21 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in children for use in contrast enhanced computed tomography of the abdomen. Precautions See PRECAUTIONS—General. Adverse Reactions Oral administration of OMNIPAQUE is most often associated with mild, transient diarrhea especially when high concentrations and large volumes are administered. Nausea, vomiting, and moderate diarrhea have also been reported following orally administered OMNIPAQUE, but much less frequently. For CT examinations using dilute oral plus intravenous contrast medium, adverse events are more likely to be associated with the intravenous injection than the hypotonic oral solution. It should be noted that serious or anaphylactoid reactions that may occur with intravascular iodinated media are possible following administration by other routes. Adults In controlled clinical trials involving 54 adult patients for oral pass-thru examination of the gastrointestinal tract using OMNIPAQUE 350, the following adverse reactions were reported: diarrhea (42%), nausea (15%), vomiting (11%), abdominal pain (7%), flatulence (2%), and headache (2%). In controlled clinical studies involving 44 adult patients for dilute oral plus intravenous CT examination of the gastrointestinal tract using OMNIPAQUE 300, adverse reactions were limited to a single report of vomiting (2%). Children In controlled clinical studies involving 58 pediatric patients for examination of the gastrointestinal tract at a concentration of 300 mgI/mL, the following adverse reactions were reported: diarrhea (36%), vomiting (9%), nausea (5%), fever (5%), hypotension (2%), abdominal pain (2%), and urticaria (2%). In clinical studies an increased frequency and severity of diarrhea was noted with an increase in the administered concentration and dose of the radiocontrast agent. In controlled clinical studies involving 69 pediatric patients for dilute oral plus intravenous CT examination of the gastrointestinal tract using OMNIPAQUE 300, adverse reactions were limited to a single report of vomiting (1.4%). Dosage and Administration Adults The recommended dosage of undiluted OMNIPAQUE 350 at a concentration of 350 mgI/mL for oral pass-thru examination of the gastrointestinal tract in adults is 50 mL to 100 mL depending on the nature of the examination and the size of the patient. The recommended oral dosage of OMNIPAQUE diluted to concentrations of 6 mgI/mL to 9 mgI/mL for contrast enhanced computed tomography of the abdomen in adults is 500 mL to 1000 mL. Smaller administered volumes are needed as the concentration of the final solution is increased (see Table below). In conjunction with dilute oral administration, the recommended dosage of OMNIPAQUE 300 administered intravenously is 100 mL to 150 mL. The oral dose is administered about 20 to 40 minutes prior to the intravenous dose and image acquisition. Children The dosage of undiluted OMNIPAQUE 300 at a concentration of 300 mgI/mL, is dependent on the nature of the examination and the size of the patient. Based on clinical experience, it is recommended that OMNIPAQUE 180 (available in single use vials), be used in children less than 3 months of age. OMNIPAQUE 300 may be used in children 3 months of age and older. The following dosage guidelines are recommended: Age Volume of OMNIPAQUE Less than 3 months 5 — 30 mL Three months to 3 years Up to 60 mL Four years to 10 years Up to 80 mL Greater than 10 years Up to 100 mL When given rectally, larger volumes may be used. The recommended oral dosage of OMNIPAQUE diluted to concentrations of 9 mgI/mL to 21 mgI/mL for contrast enhanced computed tomography of the abdomen in children is 180 mL to 750 mL. Smaller administered volumes are needed as the concentration of the final solution is increased (see Table below). The total oral dose in grams of iodine should generally not exceed 5 gI for children under 3 years of age and 10 gI for children from 3 to 18 years of age. The oral dosage may be given all at once or over a period of 30 to 45 minutes if there is difficulty in consuming the required volume. In conjunction with dilute oral administration the recommended dosage of OMNIPAQUE 300 is 2.0 mL/kg when administered intravenously with a range of 1.0 mL/kg to 2.0 mL/kg. Dosage for infants and children should be administered in proportion to age and body weight. The total intravenously administered dose should not exceed 3 mL/kg. The oral dose is administered about 30 to 60 minutes prior to the intravenous dose and image acquisition. OMNIPAQUE may be diluted with water or beverage as follows: Add To Stock Concentration of OMNIPAQUE (mgI/mL) Volume (mL) Water, Carbonated Beverage, Milk, or Juice (mL) 300 20 980 350 17 983 300 30 970 350 26 974 300 40 960 350 35 965 300 50 950 350 43 957 300 60 940 350 52 948 300 70 930 350 60 940 Dilutions of OMNIPAQUE should be prepared just prior to use and any unused portion discarded after the procedure. Launch Date 1985
Cardiovascular diseases 72 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018956s095,020608s031lbl.pdf	Diagnostic	Approved 8583	OMNIPAQUE 300 Approved Use —Intrathecal OMNIPAQUE 300 is indicated for intrathecal administration in adults including myelography (lumbar, thoracic, cervical, total columnar) and in contrast enhancement for computerized tomography (myelography, cisternography, ventriculography)., INDICATIONS AND USAGE, GENERAL—Intravascular OMNIPAQUE 350 is indicated in adults for angiocardiography (ventriculography, selective coronary arteriography), aortography including studies of the aortic root, aortic arch, ascending aorta, abdominal aorta and its branches, contrast enhancement for computed tomographic head and body imaging, intravenous digital subtraction angiography of the head, neck, abdominal, renal and peripheral vessels, peripheral arteriography, and excretory urography. OMNIPAQUE 350 is indicated in children for angiocardiography (ventriculography, pulmonary arteriography, and venography; studies of the collateral arteries and aortography, including the aortic root, aortic arch, ascending and descending aorta). OMNIPAQUE 300 is indicated in adults for aortography including studies of the aortic arch, abdominal aorta and its branches, contrast enhancement for computed tomographic head and body imaging, cerebral arteriography, peripheral venography (phlebography), and excretory urography. OMNIPAQUE 300 is indicated in children for angiocardiography (ventriculography), excretory urography, and contrast enhancement for computed tomographic head imaging., INDIVIDUAL INDICATIONS AND USAGE, INDICATIONS AND USAGE, GENERAL—Oral/Body Cavity Use OMNIPAQUE 300 and OMNIPAQUE 350 have osmolalities from approximately 1.6 to 3.0 times that of plasma (285 mOsm/kg water) and are hypertonic under conditions of use. Adults OMNIPAQUE 350 is indicated in adults for arthrography and oral pass-thru examination of the gastrointestinal tract. OMNIPAQUE 300 is indicated in adults for arthrography and hysterosalpingography. OMNIPAQUE diluted to concentrations from 6 mgI/mL to 9 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously is indicated in adults for contrast enhanced computed tomography of the abdomen. Children OMNIPAQUE 300 is indicated in children for examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 50 mgI/mL to 100 mgI/mL is indicated in children for voiding cystourethrography. OMNIPAQUE diluted to concentrations from 9 mgI/mL to 21 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in children for use in contrast enhanced computed tomography of the abdomen., INDIVIDUAL INDICATIONS AND USAGE Oral Use Adults OMNIPAQUE 350 at a concentration of 350 mgI/mL is indicated in adults for use in oral pass-thru examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 6 mgI/mL to 9 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in adults for use in contrast enhanced computed tomography of the abdomen. Dilute oral plus intravenous OMNIPAQUE may be useful when unenhanced imaging does not provide sufficient delineation between normal loops of the bowel and adjacent organs or areas of suspected pathology. Children OMNIPAQUE 300 at a concentration of 300 mgI/mL administered orally or rectally is indicated in children for use in examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 9 mgI/mL to 21 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in children for use in contrast enhanced computed tomography of the abdomen. Precautions See PRECAUTIONS—General. Adverse Reactions Oral administration of OMNIPAQUE is most often associated with mild, transient diarrhea especially when high concentrations and large volumes are administered. Nausea, vomiting, and moderate diarrhea have also been reported following orally administered OMNIPAQUE, but much less frequently. For CT examinations using dilute oral plus intravenous contrast medium, adverse events are more likely to be associated with the intravenous injection than the hypotonic oral solution. It should be noted that serious or anaphylactoid reactions that may occur with intravascular iodinated media are possible following administration by other routes. Adults In controlled clinical trials involving 54 adult patients for oral pass-thru examination of the gastrointestinal tract using OMNIPAQUE 350, the following adverse reactions were reported: diarrhea (42%), nausea (15%), vomiting (11%), abdominal pain (7%), flatulence (2%), and headache (2%). In controlled clinical studies involving 44 adult patients for dilute oral plus intravenous CT examination of the gastrointestinal tract using OMNIPAQUE 300, adverse reactions were limited to a single report of vomiting (2%). Children In controlled clinical studies involving 58 pediatric patients for examination of the gastrointestinal tract at a concentration of 300 mgI/mL, the following adverse reactions were reported: diarrhea (36%), vomiting (9%), nausea (5%), fever (5%), hypotension (2%), abdominal pain (2%), and urticaria (2%). In clinical studies an increased frequency and severity of diarrhea was noted with an increase in the administered concentration and dose of the radiocontrast agent. In controlled clinical studies involving 69 pediatric patients for dilute oral plus intravenous CT examination of the gastrointestinal tract using OMNIPAQUE 300, adverse reactions were limited to a single report of vomiting (1.4%). Dosage and Administration Adults The recommended dosage of undiluted OMNIPAQUE 350 at a concentration of 350 mgI/mL for oral pass-thru examination of the gastrointestinal tract in adults is 50 mL to 100 mL depending on the nature of the examination and the size of the patient. The recommended oral dosage of OMNIPAQUE diluted to concentrations of 6 mgI/mL to 9 mgI/mL for contrast enhanced computed tomography of the abdomen in adults is 500 mL to 1000 mL. Smaller administered volumes are needed as the concentration of the final solution is increased (see Table below). In conjunction with dilute oral administration, the recommended dosage of OMNIPAQUE 300 administered intravenously is 100 mL to 150 mL. The oral dose is administered about 20 to 40 minutes prior to the intravenous dose and image acquisition. Children The dosage of undiluted OMNIPAQUE 300 at a concentration of 300 mgI/mL, is dependent on the nature of the examination and the size of the patient. Based on clinical experience, it is recommended that OMNIPAQUE 180 (available in single use vials), be used in children less than 3 months of age. OMNIPAQUE 300 may be used in children 3 months of age and older. The following dosage guidelines are recommended: Age Volume of OMNIPAQUE Less than 3 months 5 — 30 mL Three months to 3 years Up to 60 mL Four years to 10 years Up to 80 mL Greater than 10 years Up to 100 mL When given rectally, larger volumes may be used. The recommended oral dosage of OMNIPAQUE diluted to concentrations of 9 mgI/mL to 21 mgI/mL for contrast enhanced computed tomography of the abdomen in children is 180 mL to 750 mL. Smaller administered volumes are needed as the concentration of the final solution is increased (see Table below). The total oral dose in grams of iodine should generally not exceed 5 gI for children under 3 years of age and 10 gI for children from 3 to 18 years of age. The oral dosage may be given all at once or over a period of 30 to 45 minutes if there is difficulty in consuming the required volume. In conjunction with dilute oral administration the recommended dosage of OMNIPAQUE 300 is 2.0 mL/kg when administered intravenously with a range of 1.0 mL/kg to 2.0 mL/kg. Dosage for infants and children should be administered in proportion to age and body weight. The total intravenously administered dose should not exceed 3 mL/kg. The oral dose is administered about 30 to 60 minutes prior to the intravenous dose and image acquisition. OMNIPAQUE may be diluted with water or beverage as follows: Add To Stock Concentration of OMNIPAQUE (mgI/mL) Volume (mL) Water, Carbonated Beverage, Milk, or Juice (mL) 300 20 980 350 17 983 300 30 970 350 26 974 300 40 960 350 35 965 300 50 950 350 43 957 300 60 940 350 52 948 300 70 930 350 60 940 Dilutions of OMNIPAQUE should be prepared just prior to use and any unused portion discarded after the procedure. Launch Date 1985
Urinary system disease 13 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018956s095,020608s031lbl.pdf	Diagnostic	Approved 8583	OMNIPAQUE 300 Approved Use —Intrathecal OMNIPAQUE 300 is indicated for intrathecal administration in adults including myelography (lumbar, thoracic, cervical, total columnar) and in contrast enhancement for computerized tomography (myelography, cisternography, ventriculography)., INDICATIONS AND USAGE, GENERAL—Intravascular OMNIPAQUE 350 is indicated in adults for angiocardiography (ventriculography, selective coronary arteriography), aortography including studies of the aortic root, aortic arch, ascending aorta, abdominal aorta and its branches, contrast enhancement for computed tomographic head and body imaging, intravenous digital subtraction angiography of the head, neck, abdominal, renal and peripheral vessels, peripheral arteriography, and excretory urography. OMNIPAQUE 350 is indicated in children for angiocardiography (ventriculography, pulmonary arteriography, and venography; studies of the collateral arteries and aortography, including the aortic root, aortic arch, ascending and descending aorta). OMNIPAQUE 300 is indicated in adults for aortography including studies of the aortic arch, abdominal aorta and its branches, contrast enhancement for computed tomographic head and body imaging, cerebral arteriography, peripheral venography (phlebography), and excretory urography. OMNIPAQUE 300 is indicated in children for angiocardiography (ventriculography), excretory urography, and contrast enhancement for computed tomographic head imaging., INDIVIDUAL INDICATIONS AND USAGE, INDICATIONS AND USAGE, GENERAL—Oral/Body Cavity Use OMNIPAQUE 300 and OMNIPAQUE 350 have osmolalities from approximately 1.6 to 3.0 times that of plasma (285 mOsm/kg water) and are hypertonic under conditions of use. Adults OMNIPAQUE 350 is indicated in adults for arthrography and oral pass-thru examination of the gastrointestinal tract. OMNIPAQUE 300 is indicated in adults for arthrography and hysterosalpingography. OMNIPAQUE diluted to concentrations from 6 mgI/mL to 9 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously is indicated in adults for contrast enhanced computed tomography of the abdomen. Children OMNIPAQUE 300 is indicated in children for examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 50 mgI/mL to 100 mgI/mL is indicated in children for voiding cystourethrography. OMNIPAQUE diluted to concentrations from 9 mgI/mL to 21 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in children for use in contrast enhanced computed tomography of the abdomen., INDIVIDUAL INDICATIONS AND USAGE Oral Use Adults OMNIPAQUE 350 at a concentration of 350 mgI/mL is indicated in adults for use in oral pass-thru examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 6 mgI/mL to 9 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in adults for use in contrast enhanced computed tomography of the abdomen. Dilute oral plus intravenous OMNIPAQUE may be useful when unenhanced imaging does not provide sufficient delineation between normal loops of the bowel and adjacent organs or areas of suspected pathology. Children OMNIPAQUE 300 at a concentration of 300 mgI/mL administered orally or rectally is indicated in children for use in examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 9 mgI/mL to 21 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in children for use in contrast enhanced computed tomography of the abdomen. Precautions See PRECAUTIONS—General. Adverse Reactions Oral administration of OMNIPAQUE is most often associated with mild, transient diarrhea especially when high concentrations and large volumes are administered. Nausea, vomiting, and moderate diarrhea have also been reported following orally administered OMNIPAQUE, but much less frequently. For CT examinations using dilute oral plus intravenous contrast medium, adverse events are more likely to be associated with the intravenous injection than the hypotonic oral solution. It should be noted that serious or anaphylactoid reactions that may occur with intravascular iodinated media are possible following administration by other routes. Adults In controlled clinical trials involving 54 adult patients for oral pass-thru examination of the gastrointestinal tract using OMNIPAQUE 350, the following adverse reactions were reported: diarrhea (42%), nausea (15%), vomiting (11%), abdominal pain (7%), flatulence (2%), and headache (2%). In controlled clinical studies involving 44 adult patients for dilute oral plus intravenous CT examination of the gastrointestinal tract using OMNIPAQUE 300, adverse reactions were limited to a single report of vomiting (2%). Children In controlled clinical studies involving 58 pediatric patients for examination of the gastrointestinal tract at a concentration of 300 mgI/mL, the following adverse reactions were reported: diarrhea (36%), vomiting (9%), nausea (5%), fever (5%), hypotension (2%), abdominal pain (2%), and urticaria (2%). In clinical studies an increased frequency and severity of diarrhea was noted with an increase in the administered concentration and dose of the radiocontrast agent. In controlled clinical studies involving 69 pediatric patients for dilute oral plus intravenous CT examination of the gastrointestinal tract using OMNIPAQUE 300, adverse reactions were limited to a single report of vomiting (1.4%). Dosage and Administration Adults The recommended dosage of undiluted OMNIPAQUE 350 at a concentration of 350 mgI/mL for oral pass-thru examination of the gastrointestinal tract in adults is 50 mL to 100 mL depending on the nature of the examination and the size of the patient. The recommended oral dosage of OMNIPAQUE diluted to concentrations of 6 mgI/mL to 9 mgI/mL for contrast enhanced computed tomography of the abdomen in adults is 500 mL to 1000 mL. Smaller administered volumes are needed as the concentration of the final solution is increased (see Table below). In conjunction with dilute oral administration, the recommended dosage of OMNIPAQUE 300 administered intravenously is 100 mL to 150 mL. The oral dose is administered about 20 to 40 minutes prior to the intravenous dose and image acquisition. Children The dosage of undiluted OMNIPAQUE 300 at a concentration of 300 mgI/mL, is dependent on the nature of the examination and the size of the patient. Based on clinical experience, it is recommended that OMNIPAQUE 180 (available in single use vials), be used in children less than 3 months of age. OMNIPAQUE 300 may be used in children 3 months of age and older. The following dosage guidelines are recommended: Age Volume of OMNIPAQUE Less than 3 months 5 — 30 mL Three months to 3 years Up to 60 mL Four years to 10 years Up to 80 mL Greater than 10 years Up to 100 mL When given rectally, larger volumes may be used. The recommended oral dosage of OMNIPAQUE diluted to concentrations of 9 mgI/mL to 21 mgI/mL for contrast enhanced computed tomography of the abdomen in children is 180 mL to 750 mL. Smaller administered volumes are needed as the concentration of the final solution is increased (see Table below). The total oral dose in grams of iodine should generally not exceed 5 gI for children under 3 years of age and 10 gI for children from 3 to 18 years of age. The oral dosage may be given all at once or over a period of 30 to 45 minutes if there is difficulty in consuming the required volume. In conjunction with dilute oral administration the recommended dosage of OMNIPAQUE 300 is 2.0 mL/kg when administered intravenously with a range of 1.0 mL/kg to 2.0 mL/kg. Dosage for infants and children should be administered in proportion to age and body weight. The total intravenously administered dose should not exceed 3 mL/kg. The oral dose is administered about 30 to 60 minutes prior to the intravenous dose and image acquisition. OMNIPAQUE may be diluted with water or beverage as follows: Add To Stock Concentration of OMNIPAQUE (mgI/mL) Volume (mL) Water, Carbonated Beverage, Milk, or Juice (mL) 300 20 980 350 17 983 300 30 970 350 26 974 300 40 960 350 35 965 300 50 950 350 43 957 300 60 940 350 52 948 300 70 930 350 60 940 Dilutions of OMNIPAQUE should be prepared just prior to use and any unused portion discarded after the procedure. Launch Date 1985
Gastrointestinal disorders 94 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018956s095,020608s031lbl.pdf	Diagnostic	Approved 8583	OMNIPAQUE 300 Approved Use —Intrathecal OMNIPAQUE 300 is indicated for intrathecal administration in adults including myelography (lumbar, thoracic, cervical, total columnar) and in contrast enhancement for computerized tomography (myelography, cisternography, ventriculography)., INDICATIONS AND USAGE, GENERAL—Intravascular OMNIPAQUE 350 is indicated in adults for angiocardiography (ventriculography, selective coronary arteriography), aortography including studies of the aortic root, aortic arch, ascending aorta, abdominal aorta and its branches, contrast enhancement for computed tomographic head and body imaging, intravenous digital subtraction angiography of the head, neck, abdominal, renal and peripheral vessels, peripheral arteriography, and excretory urography. OMNIPAQUE 350 is indicated in children for angiocardiography (ventriculography, pulmonary arteriography, and venography; studies of the collateral arteries and aortography, including the aortic root, aortic arch, ascending and descending aorta). OMNIPAQUE 300 is indicated in adults for aortography including studies of the aortic arch, abdominal aorta and its branches, contrast enhancement for computed tomographic head and body imaging, cerebral arteriography, peripheral venography (phlebography), and excretory urography. OMNIPAQUE 300 is indicated in children for angiocardiography (ventriculography), excretory urography, and contrast enhancement for computed tomographic head imaging., INDIVIDUAL INDICATIONS AND USAGE, INDICATIONS AND USAGE, GENERAL—Oral/Body Cavity Use OMNIPAQUE 300 and OMNIPAQUE 350 have osmolalities from approximately 1.6 to 3.0 times that of plasma (285 mOsm/kg water) and are hypertonic under conditions of use. Adults OMNIPAQUE 350 is indicated in adults for arthrography and oral pass-thru examination of the gastrointestinal tract. OMNIPAQUE 300 is indicated in adults for arthrography and hysterosalpingography. OMNIPAQUE diluted to concentrations from 6 mgI/mL to 9 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously is indicated in adults for contrast enhanced computed tomography of the abdomen. Children OMNIPAQUE 300 is indicated in children for examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 50 mgI/mL to 100 mgI/mL is indicated in children for voiding cystourethrography. OMNIPAQUE diluted to concentrations from 9 mgI/mL to 21 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in children for use in contrast enhanced computed tomography of the abdomen., INDIVIDUAL INDICATIONS AND USAGE Oral Use Adults OMNIPAQUE 350 at a concentration of 350 mgI/mL is indicated in adults for use in oral pass-thru examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 6 mgI/mL to 9 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in adults for use in contrast enhanced computed tomography of the abdomen. Dilute oral plus intravenous OMNIPAQUE may be useful when unenhanced imaging does not provide sufficient delineation between normal loops of the bowel and adjacent organs or areas of suspected pathology. Children OMNIPAQUE 300 at a concentration of 300 mgI/mL administered orally or rectally is indicated in children for use in examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 9 mgI/mL to 21 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in children for use in contrast enhanced computed tomography of the abdomen. Precautions See PRECAUTIONS—General. Adverse Reactions Oral administration of OMNIPAQUE is most often associated with mild, transient diarrhea especially when high concentrations and large volumes are administered. Nausea, vomiting, and moderate diarrhea have also been reported following orally administered OMNIPAQUE, but much less frequently. For CT examinations using dilute oral plus intravenous contrast medium, adverse events are more likely to be associated with the intravenous injection than the hypotonic oral solution. It should be noted that serious or anaphylactoid reactions that may occur with intravascular iodinated media are possible following administration by other routes. Adults In controlled clinical trials involving 54 adult patients for oral pass-thru examination of the gastrointestinal tract using OMNIPAQUE 350, the following adverse reactions were reported: diarrhea (42%), nausea (15%), vomiting (11%), abdominal pain (7%), flatulence (2%), and headache (2%). In controlled clinical studies involving 44 adult patients for dilute oral plus intravenous CT examination of the gastrointestinal tract using OMNIPAQUE 300, adverse reactions were limited to a single report of vomiting (2%). Children In controlled clinical studies involving 58 pediatric patients for examination of the gastrointestinal tract at a concentration of 300 mgI/mL, the following adverse reactions were reported: diarrhea (36%), vomiting (9%), nausea (5%), fever (5%), hypotension (2%), abdominal pain (2%), and urticaria (2%). In clinical studies an increased frequency and severity of diarrhea was noted with an increase in the administered concentration and dose of the radiocontrast agent. In controlled clinical studies involving 69 pediatric patients for dilute oral plus intravenous CT examination of the gastrointestinal tract using OMNIPAQUE 300, adverse reactions were limited to a single report of vomiting (1.4%). Dosage and Administration Adults The recommended dosage of undiluted OMNIPAQUE 350 at a concentration of 350 mgI/mL for oral pass-thru examination of the gastrointestinal tract in adults is 50 mL to 100 mL depending on the nature of the examination and the size of the patient. The recommended oral dosage of OMNIPAQUE diluted to concentrations of 6 mgI/mL to 9 mgI/mL for contrast enhanced computed tomography of the abdomen in adults is 500 mL to 1000 mL. Smaller administered volumes are needed as the concentration of the final solution is increased (see Table below). In conjunction with dilute oral administration, the recommended dosage of OMNIPAQUE 300 administered intravenously is 100 mL to 150 mL. The oral dose is administered about 20 to 40 minutes prior to the intravenous dose and image acquisition. Children The dosage of undiluted OMNIPAQUE 300 at a concentration of 300 mgI/mL, is dependent on the nature of the examination and the size of the patient. Based on clinical experience, it is recommended that OMNIPAQUE 180 (available in single use vials), be used in children less than 3 months of age. OMNIPAQUE 300 may be used in children 3 months of age and older. The following dosage guidelines are recommended: Age Volume of OMNIPAQUE Less than 3 months 5 — 30 mL Three months to 3 years Up to 60 mL Four years to 10 years Up to 80 mL Greater than 10 years Up to 100 mL When given rectally, larger volumes may be used. The recommended oral dosage of OMNIPAQUE diluted to concentrations of 9 mgI/mL to 21 mgI/mL for contrast enhanced computed tomography of the abdomen in children is 180 mL to 750 mL. Smaller administered volumes are needed as the concentration of the final solution is increased (see Table below). The total oral dose in grams of iodine should generally not exceed 5 gI for children under 3 years of age and 10 gI for children from 3 to 18 years of age. The oral dosage may be given all at once or over a period of 30 to 45 minutes if there is difficulty in consuming the required volume. In conjunction with dilute oral administration the recommended dosage of OMNIPAQUE 300 is 2.0 mL/kg when administered intravenously with a range of 1.0 mL/kg to 2.0 mL/kg. Dosage for infants and children should be administered in proportion to age and body weight. The total intravenously administered dose should not exceed 3 mL/kg. The oral dose is administered about 30 to 60 minutes prior to the intravenous dose and image acquisition. OMNIPAQUE may be diluted with water or beverage as follows: Add To Stock Concentration of OMNIPAQUE (mgI/mL) Volume (mL) Water, Carbonated Beverage, Milk, or Juice (mL) 300 20 980 350 17 983 300 30 970 350 26 974 300 40 960 350 35 965 300 50 950 350 43 957 300 60 940 350 52 948 300 70 930 350 60 940 Dilutions of OMNIPAQUE should be prepared just prior to use and any unused portion discarded after the procedure. Launch Date 1985
Glioma 25 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018956s095,020608s031lbl.pdf	Diagnostic	Approved 8583	OMNIPAQUE 300 Approved Use —Intrathecal OMNIPAQUE 300 is indicated for intrathecal administration in adults including myelography (lumbar, thoracic, cervical, total columnar) and in contrast enhancement for computerized tomography (myelography, cisternography, ventriculography)., INDICATIONS AND USAGE, GENERAL—Intravascular OMNIPAQUE 350 is indicated in adults for angiocardiography (ventriculography, selective coronary arteriography), aortography including studies of the aortic root, aortic arch, ascending aorta, abdominal aorta and its branches, contrast enhancement for computed tomographic head and body imaging, intravenous digital subtraction angiography of the head, neck, abdominal, renal and peripheral vessels, peripheral arteriography, and excretory urography. OMNIPAQUE 350 is indicated in children for angiocardiography (ventriculography, pulmonary arteriography, and venography; studies of the collateral arteries and aortography, including the aortic root, aortic arch, ascending and descending aorta). OMNIPAQUE 300 is indicated in adults for aortography including studies of the aortic arch, abdominal aorta and its branches, contrast enhancement for computed tomographic head and body imaging, cerebral arteriography, peripheral venography (phlebography), and excretory urography. OMNIPAQUE 300 is indicated in children for angiocardiography (ventriculography), excretory urography, and contrast enhancement for computed tomographic head imaging., INDIVIDUAL INDICATIONS AND USAGE, INDICATIONS AND USAGE, GENERAL—Oral/Body Cavity Use OMNIPAQUE 300 and OMNIPAQUE 350 have osmolalities from approximately 1.6 to 3.0 times that of plasma (285 mOsm/kg water) and are hypertonic under conditions of use. Adults OMNIPAQUE 350 is indicated in adults for arthrography and oral pass-thru examination of the gastrointestinal tract. OMNIPAQUE 300 is indicated in adults for arthrography and hysterosalpingography. OMNIPAQUE diluted to concentrations from 6 mgI/mL to 9 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously is indicated in adults for contrast enhanced computed tomography of the abdomen. Children OMNIPAQUE 300 is indicated in children for examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 50 mgI/mL to 100 mgI/mL is indicated in children for voiding cystourethrography. OMNIPAQUE diluted to concentrations from 9 mgI/mL to 21 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in children for use in contrast enhanced computed tomography of the abdomen., INDIVIDUAL INDICATIONS AND USAGE Oral Use Adults OMNIPAQUE 350 at a concentration of 350 mgI/mL is indicated in adults for use in oral pass-thru examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 6 mgI/mL to 9 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in adults for use in contrast enhanced computed tomography of the abdomen. Dilute oral plus intravenous OMNIPAQUE may be useful when unenhanced imaging does not provide sufficient delineation between normal loops of the bowel and adjacent organs or areas of suspected pathology. Children OMNIPAQUE 300 at a concentration of 300 mgI/mL administered orally or rectally is indicated in children for use in examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 9 mgI/mL to 21 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in children for use in contrast enhanced computed tomography of the abdomen. Precautions See PRECAUTIONS—General. Adverse Reactions Oral administration of OMNIPAQUE is most often associated with mild, transient diarrhea especially when high concentrations and large volumes are administered. Nausea, vomiting, and moderate diarrhea have also been reported following orally administered OMNIPAQUE, but much less frequently. For CT examinations using dilute oral plus intravenous contrast medium, adverse events are more likely to be associated with the intravenous injection than the hypotonic oral solution. It should be noted that serious or anaphylactoid reactions that may occur with intravascular iodinated media are possible following administration by other routes. Adults In controlled clinical trials involving 54 adult patients for oral pass-thru examination of the gastrointestinal tract using OMNIPAQUE 350, the following adverse reactions were reported: diarrhea (42%), nausea (15%), vomiting (11%), abdominal pain (7%), flatulence (2%), and headache (2%). In controlled clinical studies involving 44 adult patients for dilute oral plus intravenous CT examination of the gastrointestinal tract using OMNIPAQUE 300, adverse reactions were limited to a single report of vomiting (2%). Children In controlled clinical studies involving 58 pediatric patients for examination of the gastrointestinal tract at a concentration of 300 mgI/mL, the following adverse reactions were reported: diarrhea (36%), vomiting (9%), nausea (5%), fever (5%), hypotension (2%), abdominal pain (2%), and urticaria (2%). In clinical studies an increased frequency and severity of diarrhea was noted with an increase in the administered concentration and dose of the radiocontrast agent. In controlled clinical studies involving 69 pediatric patients for dilute oral plus intravenous CT examination of the gastrointestinal tract using OMNIPAQUE 300, adverse reactions were limited to a single report of vomiting (1.4%). Dosage and Administration Adults The recommended dosage of undiluted OMNIPAQUE 350 at a concentration of 350 mgI/mL for oral pass-thru examination of the gastrointestinal tract in adults is 50 mL to 100 mL depending on the nature of the examination and the size of the patient. The recommended oral dosage of OMNIPAQUE diluted to concentrations of 6 mgI/mL to 9 mgI/mL for contrast enhanced computed tomography of the abdomen in adults is 500 mL to 1000 mL. Smaller administered volumes are needed as the concentration of the final solution is increased (see Table below). In conjunction with dilute oral administration, the recommended dosage of OMNIPAQUE 300 administered intravenously is 100 mL to 150 mL. The oral dose is administered about 20 to 40 minutes prior to the intravenous dose and image acquisition. Children The dosage of undiluted OMNIPAQUE 300 at a concentration of 300 mgI/mL, is dependent on the nature of the examination and the size of the patient. Based on clinical experience, it is recommended that OMNIPAQUE 180 (available in single use vials), be used in children less than 3 months of age. OMNIPAQUE 300 may be used in children 3 months of age and older. The following dosage guidelines are recommended: Age Volume of OMNIPAQUE Less than 3 months 5 — 30 mL Three months to 3 years Up to 60 mL Four years to 10 years Up to 80 mL Greater than 10 years Up to 100 mL When given rectally, larger volumes may be used. The recommended oral dosage of OMNIPAQUE diluted to concentrations of 9 mgI/mL to 21 mgI/mL for contrast enhanced computed tomography of the abdomen in children is 180 mL to 750 mL. Smaller administered volumes are needed as the concentration of the final solution is increased (see Table below). The total oral dose in grams of iodine should generally not exceed 5 gI for children under 3 years of age and 10 gI for children from 3 to 18 years of age. The oral dosage may be given all at once or over a period of 30 to 45 minutes if there is difficulty in consuming the required volume. In conjunction with dilute oral administration the recommended dosage of OMNIPAQUE 300 is 2.0 mL/kg when administered intravenously with a range of 1.0 mL/kg to 2.0 mL/kg. Dosage for infants and children should be administered in proportion to age and body weight. The total intravenously administered dose should not exceed 3 mL/kg. The oral dose is administered about 30 to 60 minutes prior to the intravenous dose and image acquisition. OMNIPAQUE may be diluted with water or beverage as follows: Add To Stock Concentration of OMNIPAQUE (mgI/mL) Volume (mL) Water, Carbonated Beverage, Milk, or Juice (mL) 300 20 980 350 17 983 300 30 970 350 26 974 300 40 960 350 35 965 300 50 950 350 43 957 300 60 940 350 52 948 300 70 930 350 60 940 Dilutions of OMNIPAQUE should be prepared just prior to use and any unused portion discarded after the procedure. Launch Date 1985

C_max

Value	Dose	Co-administered	Analyte	Population
16.395 μg/mL OTHER https://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=1278&context=etd&httpsredir=1&referer=	647.11 mg single, subcutaneous dose: 647.11 mg route of administration: Subcutaneous experiment type: SINGLE co-administered:		IOHEXOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
6365.609 μg × min/mL OTHER https://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=1278&context=etd&httpsredir=1&referer=	647.11 mg single, subcutaneous dose: 647.11 mg route of administration: Subcutaneous experiment type: SINGLE co-administered:		IOHEXOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
119 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6408018	269.63 mg/kg single, intravenous dose: 269.63 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	IOHEXOL serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
139.132 min OTHER https://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=1278&context=etd&httpsredir=1&referer=	647.11 mg single, subcutaneous dose: 647.11 mg route of administration: Subcutaneous experiment type: SINGLE co-administered:	IOHEXOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
20 min DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018956s099lbl.pdf		IOHEXOL blood	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
100% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018956s099lbl.pdf			IOHEXOL blood	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
1510 mg/kg 1 times / day single, intraarterial Highest studied dose Dose: 1510 mg/kg, 1 times / day Route: intraarterial Route: single Dose: 1510 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3993426/ https://pubmed.ncbi.nlm.nih.gov/6382927/	unhealthy Health Status: unhealthy Sources: https://pubmed.ncbi.nlm.nih.gov/3993426/ https://pubmed.ncbi.nlm.nih.gov/6382927/	Sources: https://pubmed.ncbi.nlm.nih.gov/3993426/ https://pubmed.ncbi.nlm.nih.gov/6382927/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP 110

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP 150	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/32948918/ Page: 7.0	not significant

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:31709	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31709
ChemicalBook	CB2262877	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2262877
eMolecules	537156	https://www.emolecules.com/cgi-bin/more?vid=537156
MolPort	MolPort-003-931-371	https://www.molport.com/shop/molecule-link/MolPort-003-931-371

PubMed

Title	Date	PubMed
Changes in the fibrinolytic system during angiography with ionic and with nonionic contrast media.	2002-03	11887944
[A differentiated approach to the diagnosis of pulmonary embolism and deep venous thrombosis using multi-slice CT].	2002-03	11885007
Comparative cytotoxicity of low-osmolar nonionic and high-osmolar ionic contrast media to dog gallbladder epithelial cells.	2002-03	11868013
Fatal cardiac arrest during infusion of nonionic contrast media in a patient with essential thrombocythemia.	2002-03	11856718
Contrast media as markers of GFR.	2002-02	11870453
Is contrast as bad as we think? Renal function after angiographic embolization of injured patients.	2002-02	11848631
Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure.	2002-02	11805176
Optimization of contrast agent volume for helical CT in the diagnostic assessment of patients with severe and multiple injuries.	2002-01-22	11801913
Optimal scan delay in spiral CT for the diagnosis of acute pulmonary embolism.	2002-01-22	11801900
Transforaminal epidural steroid injections in lumbosacral radiculopathy: a prospective randomized study.	2002-01-01	11805628
Cardiac arrest after administration of Omnipaque radiocontrast medium during endoluminal repair of abdominal aortic aneurysm.	2002-01	11881869
Comments on F. Stacul: Current iodinated contrast media.	2002-01	11868110
Effect of arthrocentesis on TMJ disturbance of mouth closure with loud clicking: a preliminary study.	2002-01	11831339
Systemic platelet effects of contrast media: implications for cardiologic research and clinical practice.	2002-01	11773932
Investigations into the environmental fate and effects of iopromide (ultravist), a widely used iodinated X-ray contrast medium.	2002-01	11766804
Comparison of intraarterial and IV gadolinium-enhanced MR angiography with digital subtraction angiography for the detection of renal artery stenosis in pigs.	2002-01	11756103
Contrast media clearance in a single kidney measured on multiphasic helical CT: results in 50 patients without acute renal disorder.	2002-01	11756102
CT of duodenal angiomyolipoma [corrected].	2002-01	11756094
Acute cardiac tolerance of current contrast media and the new taxane protaxel using iopromide as carrier during porcine coronary angiography and stenting.	2002-01	11753151
Contrast media increase vascular endothelial permeability by inhibiting nitric-oxide production.	2002-01	11753149
Is contrast-related vasodilatation after intra-coronary iodixanol and iopromide in vivo endothelium-dependent?	2001-12	11888823
Sodium and water homeostasis in children with shigellosis.	2001-12	11853332
Effects of radiographic contrast media on pulmonary vascular resistance of normoxic and chronically hypoxic pulmonary hypertensive rats.	2001-12	11777768
Radiographic contrast media induced nephropathy: experimental observations and the protective effect of calcium channel blockers.	2001-12	11777767
Stabilization of the hydrophilic sphere of non-ionic monomers: are all protected in a similar way?	2001-12	11777766
Comparison of the effects of radiographic contrast media on dehydration and filterability of red blood cells from donors homozygous for hemoglobin A or hemoglobin S.	2001-11	11754395
Proteinuria and plasma total homocysteine levels in chronic renal disease patients with a normal range serum creatinine: critical impact of true glomerular filtration rate.	2001-11	11689224
The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study.	2001-11	11682661
[Diagnosis of bilateral pulmonary thrombosis by electron radiation imaging and magnetic resonance imaging].	2001-10-18	11603330
Experiences with iohexol and iodixanol during cardioangiography in an unselected patient population.	2001-10-02	11578707
Investigation of aortocoronary artery bypass grafts by multislice spiral computed tomography with electrocardiographic-gated image reconstruction.	2001-10-01	11589852
[Thyroid function after iodine-containing contrast agent administration in coronary angiography: a prospective study of euthyroid patients].	2001-10	11757471
[Impact of different iodine concentrations on abdominal enhancement in biphasic multislice helical CT (MS-CT)].	2001-10	11588683
Comparative study between gadobenate dimeglumine and gadobutrol in rats with brain ischemia: evaluation of somatosensory evoked potentials.	2001-10	11577266
Delayed exanthema to nonionic contrast medium.	2001-10	11576087
Enhanced CT in the diagnosis of acute appendicitis to evaluate the severity of disease: comparison of CT findings and histological diagnosis.	2001-09-12	11550720
Clinical application of plasma clearance of iohexol on feline patients.	2001-09	11876631
[Severe reactions to iodinated contrast agents: is anaphylaxis responsible?].	2001-09	11591924
Measurement of single kidney contrast media clearance by multiphasic spiral computed tomography: preliminary results.	2001-09	11566250
Changes in endothelial, leucocyte and platelet markers following contrast medium injection during angiography in patients with peripheral artery disease.	2001-09	11560828
CT pulmonary angiography with a macromolecular contrast medium: a comparative study versus iobitridol in rabbits.	2001-09	11547043
No evidence of accelerated loss of kidney function in living kidney donors: results from a cross-sectional follow-up.	2001-08-15	11502974
Renal effects of cardiac angiography with different low-osmolar contrast media.	2001-08-14	11499554
One-step subcellular fractionation of rat liver tissue using a Nycodenz density gradient prepared by freezing-thawing and two-dimensional sodium dodecyl sulfate electrophoresis profiles of the main fraction of organelles.	2001-08	11565782
Plasma clearance of iodine contrast media as a measure of glomerular filtration rate in critically ill patients.	2001-08	11505124
[Mesenteric panniculitis].	2001-07	11526912
Glucose alters the susceptibility of mesangial cells to contrast media.	2001-07	11496090
Contrast-medium-induced nephrotoxicity: are all answers in for acetylcysteine?	2001	11734930
Use of spiral CT and the contrast medium iohexol to determine in one session aortorenal morphology and the relative glomerular filtration rate of each kidney.	2001	11702172
Hepatic and vascular enhancement at dual-phase helical CT: comparison of Iobitridol 300 and Iohexol 300 in a prospective randomized study.	2001	11702162

Patents

Sample Use Guides

In Vivo Use Guide

Intrathecal: OMNIPAQUE 240 (concentration 240 mgI/mL) - the usual recommended total doses for use in lumbar, thoracic, cervical, and total columnar myelography in adults are 1.2 gI to 3.06 gI (6-12.5 ml). Intravascular: The recommended single injection volume of OMNIPAQUE 350 (concentration 350 mgI/mL) for angiocardiographic procedures is 40 mL with a range of 30 mL to 60 mL. Oral: The recommended dosage of undiluted OMNIPAQUE 350 (concentration of 350 mgI/mL) for oral pass-thru examination of the gastrointestinal tract in adults is 50 mL to 100 mL depending on the nature of the examination and the size of the patient.

Route of Administration: Other

In Vitro Use Guide

Diffusion of iohexol (300 and 240 mgI/ml) was studied in the cerebrospinal fluid (CSF). Test tubes containing CSF were kept in a waterbath at 37 degrees C. Contrast medium was injected along the wall into the tubes, and diffusion of contrast media in the tubes was followed with repeated computed tomography for 5 h. The contents of the tubes were then mixed by shaking, and the tubes were scanned immediately and 8 h later.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:22:15 GMT 2025` Edited by `admin` on `Mon Mar 31 18:22:15 GMT 2025`
Record UNII	4419T9MX03
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Iohexol

Official Name

English

OMNIPAQUE

Preferred Name

English

iohexol [INN]

Common Name

English

NSC-759636

Code

English

WIN-39424

Code

English

1,3-BENZENEDICARBOXAMIDE, 5-(ACETYL(2,3-DIHYDROXYPROPYL)AMINO)-N,N'-BIS(2,3-DIHYDROXYPROPYL)-2,4,6-TRIIODO

Common Name

English

N,N'-BIS(2,3-DIHYDROXYPROPYL)-5-(N-(2,3-DIHYDROXYPROPYL)ACETAMIDO)-2,4,6-TRIIODOISOPHTHALAMIDE

Systematic Name

English

IOHEXOL [USAN]

Common Name

English

IOHEXOL [ORANGE BOOK]

Common Name

English

Iohexol [WHO-DD]

Common Name

English

WIN 39424

Code

English

IOHEXOLUM [WHO-IP LATIN]

Common Name

English

IOHEXOL [JAN]

Common Name

English

IOHEXOL [EP MONOGRAPH]

Common Name

English

IOHEXOL [MART.]

Common Name

English

IOHEXOL [USP-RS]

Common Name

English

IOHEXOL [VANDF]

Common Name

English

ORALTAG

Brand Name

English

IOHEXOL [EP IMPURITY]

Common Name

English

IOHEXOL [WHO-IP]

Common Name

English

IOHEXOL [USP MONOGRAPH]

Common Name

English

IOHEXOL [MI]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000010258